Search Results
Aug 18, 2026, 09:00 ET J.P. Morgan Life Sciences Private Capital Welcomes Bruce N. Rogers, Ph.D. as Venture Partner
Therapeutic, where he originally joined as Chief Scientific Officer in 2016, built the company's platform, and delivered a portfolio of assets including MORF-057. Following Morphic's acquisition by Eli Lilly in 2024 for $3.2 billion, he transitioned to Eli Lilly as Senior Vice President and CEO of Morphic, overseeing
More news about: J.P. Morgan Asset Management
Feb 19, 2026, 12:15 ET Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
NCT06598943), a monoclonal antibody that targets neutrophil-driven inflammation, and with LY4268989 (MORF-057) (
More news about: Eli Lilly and Company
Dec 17, 2025, 17:31 ET Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight
boosting market revenues. Additionally, the expected launch of therapies such as obefazimod (Abivax), tulisokibart (Merck), Afimkibart (RVT 3101) (Roche), MORF-057 (Eli Lilly), and others will further boost the market.LAS VEGAS, Dec.
More news about: DelveInsight Business Research, LLP
Oct 27, 2025, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
NCT06598943), a monoclonal antibody that targets neutrophil-driven inflammation, and with LY4268989 (MORF-057) (
More news about: Eli Lilly and Company
Oct 07, 2025, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
NCT06598943), a monoclonal antibody that targets neutrophil-driven inflammation, and with LY4268989 (MORF-057) (
More news about: Eli Lilly and Company